Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03003962 · ClinicalTrials.gov registry record · Phase 3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

A Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
669
Enrollment target
20
Study locations

NCT03003962 is a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 669 participants. The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03003962, a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
669 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)

Conditions Studied

Non-Small-Cell Lung Carcinoma NSCLC

Interventions

  • DRUG Gemcitabine + cisplatin
  • DRUG Gemcitabine + carboplatin
  • DRUG Durvalumab (MEDI4736)
  • DRUG Paclitaxel + carboplatin
  • DRUG Pemetrexed + cisplatin

Study Locations (20)

Other

  • Research Site - Box Hill
  • Research Site - Gosford
  • Research Site - Kogarah
  • Research Site - St Leonards
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Bengbu
  • Research Site - Changchun
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Chongqing
  • Research Site - Guangzhou
  • Research Site - Guangzhou
  • Research Site - Haikou
  • Research Site - Hangzhou
  • Research Site - Hangzhou
  • Research Site - Hangzhou
  • Research Site - Hangzhou

California

  • Research Site - Anaheim

Trial Details

FieldValue
Enrollment Target 669 participants
Start Date 2017-01-02
Est. Completion 2026-06-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03003962

The ClinicalTrials.gov registry entry for NCT03003962 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 669 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small-Cell Lung Carcinoma NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine + cisplatin is the first listed.

NCT03003962 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, California.

Frequently Asked Questions

What is clinical trial NCT03003962 about?

NCT03003962 is a clinical study titled "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)". This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild...

What is the current status of trial NCT03003962?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 669 participants. The study started on 2017-01-02. Estimated completion is 2026-06-30.

What conditions does trial NCT03003962 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma NSCLC.

What interventions are being tested in trial NCT03003962?

The interventions under investigation include: Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG), Durvalumab (MEDI4736) (DRUG), Paclitaxel + carboplatin (DRUG), Pemetrexed + cisplatin (DRUG).

Who is sponsoring clinical trial NCT03003962?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03003962 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small-Cell Lung Carcinoma NSCLC

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.